Company profile ABOS

Acumen Pharmaceuticals Inc
acumen is forging a new path towards safe and effective treatments for alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic amyloid-beta oligomers. our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (aβo) in synaptic dysfunction and neurodegeneration. these early insight...s have fostered decades of research on the biology of aβo at acumen and throughout the field. we are now on the on cusp of realizing the therapeutic potential of aβo targeted drugs. Show More
Quarter analysis & expected interestLast update: February 08 2024 12:44:49.

After 39 days of this quarter the interest is at 35.0. Based on that we can calculate that during remaining 52 days it will total up to 82.0.
Acumen Pharmaceuticals expected interest is significantly higher compared to same quarter last year (+141.2%) but lower than previous quarter (-59.8%).

YearQ1Q2Q3Q4
201988
38
-56.8% QoQ
39
2.6% QoQ
71
82.1% QoQ
2020 90
2.3% YoY 26.8% QoQ
65
71.1% YoY -27.8% QoQ
103
164.1% YoY 58.5% QoQ
73
2.8% YoY -29.1% QoQ
2021 103
14.4% YoY 41.1% QoQ
262
303.1% YoY 154.4% QoQ
169
64.1% YoY -35.5% QoQ
115
57.5% YoY -32.0% QoQ
2022 64
-37.9% YoY -44.3% QoQ
72
-72.5% YoY 12.5% QoQ
194
14.8% YoY 169.4% QoQ
126
9.6% YoY -35.1% QoQ
2023 34
-46.9% YoY -73.0% QoQ
97
34.7% YoY 185.3% QoQ
253
30.4% YoY 160.8% QoQ
204
61.9% YoY -19.4% QoQ
2024 35
2.9% YoY -82.8% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Acumen Pharmaceuticals search interestLast update: February 08 2024 12:44:48.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 12:44:52.

The average 5 years interest of Acumen Pharmaceuticals was 8.79 per week.
The last year interest of Acumen Pharmaceuticals compared to the last 5 years has changed by 33.45%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 96.81%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 12:44:58.

After 39 days of this quarter the interest is at 21.0. Based on that we can calculate that during remaining 52 days it will total up to 49.0.
ACU193 expected interest is significantly lower compared to same quarter last year (-66.0%) but similar to previous quarter.

YearQ1Q2Q3Q4
2019164
128
-22.0% QoQ
94
-26.6% QoQ
106
12.8% QoQ
2020 154
-6.1% YoY 45.3% QoQ
106
-17.2% YoY -31.2% QoQ
32
-66.0% YoY -69.8% QoQ
133
25.5% YoY 315.6% QoQ
2021 94
-39.0% YoY -29.3% QoQ
102
-3.8% YoY 8.5% QoQ
80
150.0% YoY -21.6% QoQ
160
20.3% YoY 100.0% QoQ
2022 64
-31.9% YoY -60.0% QoQ
205
101.0% YoY 220.3% QoQ
69
-13.8% YoY -66.3% QoQ
72
-55.0% YoY 4.3% QoQ
2023 144
125.0% YoY 100.0% QoQ
73
-64.4% YoY -49.3% QoQ
175
153.6% YoY 139.7% QoQ
74
2.8% YoY -57.7% QoQ
2024 21
-85.4% YoY -71.6% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and ACU193 search interestLast update: February 08 2024 12:44:58.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 12:44:59.

The average 5 years interest of ACU193 was 8.62 per week.
The last year interest of ACU193 compared to the last 5 years has changed by -1.16%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -21.83%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Acumen Pharmaceuticals Alzheimer's treatment to provide analysis

Correlation between past revenue and Acumen Pharmaceuticals Alzheimer's treatment search interest

There is not enough data for Acumen Pharmaceuticals Alzheimer's treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Acumen Pharmaceuticals Alzheimer's treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Acumen Pharmaceuticals ACU193 to provide analysis

Correlation between past revenue and Acumen Pharmaceuticals ACU193 search interest

There is not enough data for Acumen Pharmaceuticals ACU193 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Acumen Pharmaceuticals ACU193 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Acumen Pharmaceuticals jobs to provide analysis

Correlation between past revenue and Acumen Pharmaceuticals jobs search interest

There is not enough data for Acumen Pharmaceuticals jobs to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Acumen Pharmaceuticals jobs to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Acumen Pharmaceuticals reviews to provide analysis

Correlation between past revenue and Acumen Pharmaceuticals reviews search interest

There is not enough data for Acumen Pharmaceuticals reviews to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Acumen Pharmaceuticals reviews to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 12:45:06.

After 39 days of this quarter the interest is at 40.0. Based on that we can calculate that during remaining 52 days it will total up to 93.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019235
57
-75.7% QoQ
46
-19.3% QoQ
81
76.1% QoQ
2020 132
-43.8% YoY 63.0% QoQ
17
-70.2% YoY -87.1% QoQ
77
67.4% YoY 352.9% QoQ
33
-59.3% YoY -57.1% QoQ
2021 69
-47.7% YoY 109.1% QoQ
223
1211.8% YoY 223.2% QoQ
203
163.6% YoY -9.0% QoQ
120
263.6% YoY -40.9% QoQ
2022 126
82.6% YoY 5.0% QoQ
92
-58.7% YoY -27.0% QoQ
245
20.7% YoY 166.3% QoQ
164
36.7% YoY -33.1% QoQ
2023 117
-7.1% YoY -28.7% QoQ
83
-9.8% YoY -29.1% QoQ
262
6.9% YoY 215.7% QoQ
111
-32.3% YoY -57.6% QoQ
2024 40
-65.8% YoY -64.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Acumen Pharmaceuticals -stock -company search interestLast update: February 08 2024 12:45:06.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 12:45:10.

The average 5 years interest of Acumen Pharmaceuticals -stock -company was 9.7 per week.
The last year interest of Acumen Pharmaceuticals -stock -company compared to the last 5 years has changed by 14.43%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by 14.79%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ABOS
Earnings date: 2024-03-25 After close
Company name: Acumen Pharmaceuticals Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-12T11:00:00Z

GlobeNewswire
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

2026-05-07T20:00:00Z

GlobeNewswire
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference

2026-05-05T20:00:00Z

GlobeNewswire
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

2026-03-26T16:32:48Z

Analyst Upgrades
BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target

2026-03-26T11:00:00Z

GlobeNewswire
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

2026-03-16T10:30:00Z

GlobeNewswire
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

2026-03-10T20:00:00Z

GlobeNewswire
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

2026-03-03T13:00:00Z

GlobeNewswire
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026

2026-01-27T10:02:36Z

Analyst Upgrades
BTIG Maintains Buy on Acumen Pharmaceuticals, Raises Price Target to $7

2025-12-02T13:00:00Z

GlobeNewswire
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

2025-11-18T17:58:15Z

Analyst Upgrades
B of A Securities Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $8

2025-11-18T13:00:00Z

GlobeNewswire
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

2025-11-17T13:00:00Z

GlobeNewswire
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer's Disease

2025-11-12T12:00:00Z

GlobeNewswire
Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights

2025-11-10T13:00:00Z

GlobeNewswire
Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors